# Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

> **NCT03485222** · PHASE4 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 84 (actual)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03485222
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-02-13
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-03-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485222, "Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03485222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*